Skip Ribbon Commands
Skip to main content
Prof Tan Louis Chew Seng

Prof Tan Louis Chew Seng

MBBS, MRCP (UK), FAMS (Neurology), FRCP (Edin)

Senior Consultant

National Neuroscience Institute

Specialty: Neurology, Neurology

Clinical Interest: Parkinson's Disease, Movement Disorders, General Neurology

Conditions Treated by this Doctor:
Parkinson's Disease and Movement Disorders.

Clinical Appointments

  • Senior Consultant Department of Neurology National Neuroscience InstituteNational Neuroscience Institute
  • Director, Research National Neuroscience InstituteNational Neuroscience Institute


Prof Louis Tan is a Senior Consultant Neurologist, Director, Research and Director, Clinical Programmes at the National Neuroscience Institute, Singapore.  He is also an Adjunct Associate Professor of Duke-NUS Graduate Medical School, Singapore.

He is Treasurer-elect of the International Parkinson and Movement Disorder Society and previously served as Chair of the Education committee and Asian-Oceanian Section of the Society.  

Upon graduating from the National University of Singapore and completing his neurology training at Tan Tock Seng Hospital, he underwent a movement disorders fellowship at the Parkinson’s Institute in Sunnyvale, California. 

His areas of specialty and research interests are Parkinson’s disease and movement disorders. He is also interested in the epidemiology, clinical studies and clinical trials in Parkinson’s disease and other movement disorders.


  • Specialist Accreditation in Neurology, Ministry of Health, Singapore, 2000
  • Member of Royal College of Physicians (MRCP, United Kingdom), 1995
  • ​MBBS National University of Singapore, 1990

Professional Appointments and Committee Memberships

  • ​Senior Consultant, Department of Neurology, National Neuroscience Institute
  • Director, Research, National Neuroscience Institute
  • Director, Clinical Programmes, National Neuroscience Institute
  • Treasurer-elect, International Parkinson and Movement Disorder Society
  • Co-Director, Parkinson’s Disease and Movement Disorders Centre, USA National Parkinson Foundation, International Centre of Excellence
  • Adjunct Associate Professor, Duke-NUS Graduate Medical School, Singapore


  • Dean’s Award for teaching excellence AY 2013/14, Yong Loo Lin School of Medicine, National University of Singapore
  • Distinguished Team Award (team lead), Singhealth Excellence Award 2015
  • President’s Distinguished Service Award 2015.  International Parkinson and Movement Disorders Society
  • Singapore Health Quality Service Award 2016, Silver
  • Distinguished Member Award.  The Japanese Society of Neurology. 57th Annual Meeting, 2016

Research Interests

  • ​Epidemiology, clinical studies and clinical trials in Parkinson's disease and other movement disorders


Selected publications from more than 100 publications:

  • Wen MC, Ng SY, Heng HS, Chao YX, Chan LL, Tan EK, Tan LC.  Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson's disease: A resting state functional MRI study.  Parkinsonism Relat Disord. 2016 Mar;24:63-8.
  • Tan LC, Methawasin K, Tan EK, Tan JH, Au WL, Yuan JM, Koh WP.  Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study.  J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):86-92.
  • Linda P. Oosterveld, John C. Allen Jr, Ebonne Y.L. Ng, Soo-Hoon Seah , Kay-Yaw Tay, Wing-Lok Au, Eng-King Tan,  Louis C.S. Tan.  Greater motor progression in Parkinson’s disease patients with LRRK2 risk variants.  Neurology. 2015 Sep 22;85(12):1039-42. 
  • YJ Zhao, HL Wee, YH Chan, SH Seah, WL Au, PN Lau, EC Pica, SC Li, N Luo and LCS Tan.  Progression of Parkinson’s Disease as Evaluated by Hoehn and Yahr Stage Transition Times.  Mov Disord 2010; 25(6):710-716.
  • LCS Tan, N Venketasubramanian, CY Hong, S Sahadevan, JJ Chin, ES Krishnamoorthy, AKY Tan, SM Saw.  Prevalence of Parkinson’s disease in Singapore: Chinese vs Malays vs Indians.  Neurology 2004; 62:1999-2004.

Research Trials

  • A multicenter, double blind, randomised, placebo-controlled, single treatment cycle, parallel evaluation of the safety, efficacy and immunogenicity of two formulations of BOTOX purified neurotoxin complex, followed by a blinded active treatment extension up to two additional treatment cycles in patients with cervical dystonia. (Co-I; sponsor: Allergan. 2008-9).
  • Singapore Millenium Foundation Translational Research Grant awarded to NNI ending 2013.  Co-PI for PD epidemiological and clinical research. 
  • An Open-label, Multicentre, Multinational Study To Assess The Feasibility Of Switching Therapy From Pramipexole Or Ropinirole To The Rotigotine Transdermal System and Its Effect On Motor And Non-motor Symptoms In Subjects with Advanced Idiopathic Parkinson's Disease.  PI; Sponsor: UCB Biosciences GmbH, 2013.
  • An Open-Label Study to Investigate the Safety and the Efficacy of Rotigotine Add-On Therapy with Low Doses of Pramipexole or Ropinirole in Patients with Advanced Parkinson's Disease.  PI; Sponsor: UCB Biosciences GmbH, 2013. 
  • Co-PI in National Medical Research Council – Translational clinical research grant for Parkinson’s disease (2014-2019 – $25 Million).